Pfizer says patient dies after receiving hemophilia drug in trial

December 24, 2025 – 9:09 AM

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. (Reuters/Mike Blake/File Photo)

How logistics industry experts plan to ‘move forward’ after COVID-19

Reasons why Filipinos love Korean culture and products

Why Batangas is the destination for budget-friendly family holidays

A patient who was being treated with Pfizer’s

PFE.N

hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects,

the company said

according to

the European Haemophilia Consortium, a

patient support group

The patient was enrolled in a study that was testing Hympavzi in patients with hemophilia A or B with or without inhibitors.

“Pfizer, together with the trial investigator and the independent external Data Monitoring Committee, are actively gathering information to better understand the complex, multi-factorial circumstances surrounding this occurrence,” the company said in a statement.

The therapy, a once-a-week injection, gained U.S. approval last year to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older

by targeting blood-clotting proteins.

Pfizer does not anticipate any impact to safety for patients treated with the drug based on its current knowledge and the overall clinical data collected to date, the company said.

Earlier this year, Pfizer said it would halt global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.

Beqvez, a one-time therapy, was approved in the U.S. for the treatment of adults with moderate to severe hemophilia B.

—Reporting by Sneha S K in Bengaluru; Editing by Anil D’Silva